rabeprazole has been researched along with Laryngitis in 4 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Laryngitis: Inflammation of the LARYNGEAL MUCOSA, including the VOCAL CORDS. Laryngitis is characterized by irritation, edema, and reduced pliability of the mucosa leading to VOICE DISORDERS such as APHONIA and HOARSENESS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, AJ | 2 |
| Liang, MJ | 2 |
| Jiang, AY | 2 |
| Lin, JK | 2 |
| Xiao, YL | 2 |
| Peng, S | 2 |
| Chen, J | 2 |
| Wen, WP | 2 |
| Chen, MH | 2 |
| Kłopocka, M | 1 |
| Sinkiewicz, A | 1 |
| Budzyński, J | 1 |
| Pulkowski, G | 1 |
| Swiatkowski, M | 1 |
| Thibeault, SL | 1 |
| Smith, ME | 1 |
| Peterson, K | 1 |
| Ylitalo-Moller, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identification of Molecular Markers of Inflammatory Mediators in Posterior Laryngitis Due to Laryngopharyngeal Reflux and Evolution With PPI Treatment[NCT00204698] | Phase 2/Phase 3 | 24 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for rabeprazole and Laryngitis
| Article | Year |
|---|---|
Improvement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Chronic Disease; Female; Human | 2004 |
3 other studies available for rabeprazole and Laryngitis
| Article | Year |
|---|---|
Comparison of patients of chronic laryngitis with and without troublesome reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Anti-Ulcer Agents; Chronic Disease; End | 2012 |
Predictors of acid suppression success in patients with chronic laryngitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Chronic Disease; Endoscopy, Digest | 2012 |
Gene expression changes of inflammatory mediators in posterior laryngitis due to laryngopharyngeal reflux and evolution with PPI treatment: a preliminary study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Biopsy; Esophageal pH Monit | 2007 |